Metabolic resuscitation in critical illness represents a paradigm shift in the management of septic shock and other life-threatening conditions, focusing on restoring cellular function through targeted supplementation of metabolic cofactors. Recent evidence has highlighted the potential of a combination of intravenous vitamin C, thiamine, and corticosteroids to modulate the inflammatory response, mitochondrial dysfunction, and oxidative stress characteristic of critical illness. This review provides a comprehensive analysis of the current understanding, clinical evidence, and practical considerations for metabolic resuscitation, with emphasis on recent advances and guideline-based recommendations for clinicians.
Critical illness, including sepsis, septic shock, and other states of systemic inflammatory response, is associated with profound metabolic disturbances. Traditional resuscitation focuses on hemodynamics, but growing evidence suggests that correction of underlying metabolic derangements is essential for optimal recovery. Metabolic resuscitation targets the restoration of cellular energy production and antioxidant capacity, aiming to improve patient outcomes by mitigating mitochondrial dysfunction and cellular hypoxia. This article reviews the pathophysiological basis, clinical evidence, and practical implications of metabolic resuscitation in critical care.
Sepsis and septic shock remain leading causes of morbidity and mortality in intensive care units globally, with mortality rates ranging from 20% to 50% depending on patient population and resource setting. The burden of critical illness extends beyond infectious etiologies, encompassing trauma, pancreatitis, and acute organ failures. The high prevalence of vitamin and cofactor deficiencies, particularly vitamin C and thiamine, in critically ill patients has been consistently documented, correlating with worse clinical outcomes and prolonged ICU stays. Addressing these metabolic deficiencies is therefore of significant clinical relevance.
Critical illness induces complex metabolic derangements, including impaired glucose metabolism, mitochondrial dysfunction, lactic acidosis, and oxidative stress. The systemic inflammatory response leads to increased production of reactive oxygen species (ROS) and depletion of endogenous antioxidants. Vitamin C acts as a key antioxidant and enzyme cofactor, supporting endothelial function and immune response. Thiamine is essential for aerobic metabolism, facilitating pyruvate dehydrogenase activity and ATP production. Corticosteroids modulate inflammation and stress response. Together, deficiency of these factors exacerbates cellular injury and organ dysfunction.
Patients at risk for metabolic derangements in critical illness include those with pre-existing malnutrition, chronic alcoholism, diabetes, renal failure, and prolonged hospitalization. The stress of acute illness further depletes endogenous stores of vitamins and cofactors, particularly in sepsis, trauma, and burns. Age, comorbidities, and delayed initiation of nutritional support compound the risk, making early identification and supplementation critical in high-risk populations.
Metabolic derangements in critical illness may manifest as refractory hypotension, persistent lactic acidosis, altered mental status, multi-organ dysfunction, and delayed recovery despite adequate hemodynamic support. Laboratory findings often reveal hypovitaminosis C, thiamine deficiency, elevated lactate, and markers of oxidative stress. Clinical suspicion should be heightened in patients with unexplained metabolic acidosis or poor response to standard resuscitative measures.
Diagnosis of metabolic abnormalities in critical illness is based on clinical context, supported by laboratory assays of vitamin C, thiamine, lactate, and other metabolic markers. However, routine measurement of these cofactors is not universally available. Hence, empiric supplementation is often considered in critically ill patients with compatible clinical features. Point-of-care testing for lactate and assessment of nutritional status are valuable adjuncts in guiding therapy.
Metabolic resuscitation involves the intravenous administration of high-dose vitamin C, thiamine, and corticosteroids as adjunctive therapy in septic shock and other forms of critical illness. Protocols typically include vitamin C (1.5 g IV every 6 hours), thiamine (200 mg IV every 12 hours), and hydrocortisone (50 mg IV every 6 hours). The rationale is to replenish depleted cofactors, reduce oxidative injury, support mitochondrial function, and attenuate the dysregulated inflammatory response. Timely initiation, ideally within the first 24 hours of shock, is associated with improved hemodynamics and organ function in some studies.
The publication of the "Marik protocol" in 2017 sparked widespread interest in metabolic resuscitation, reporting dramatic reductions in mortality among septic shock patients treated with vitamin C, thiamine, and hydrocortisone. Subsequent randomized controlled trials (RCTs), including CITRIS-ALI, VITAMINS, and LOVIT, have produced mixed results, with some showing benefit in secondary outcomes such as vasopressor use and organ dysfunction, but not in all-cause mortality. Ongoing research is exploring optimal dosing, timing, patient selection, and the potential role of other agents such as vitamin D, glutamine, and N-acetylcysteine. The heterogeneity of sepsis and metabolic phenotypes underscores the need for individualized approaches.
Current international guidelines, including those from the Surviving Sepsis Campaign, do not recommend routine use of metabolic resuscitation with vitamin C, thiamine, and corticosteroids outside of clinical trials, citing insufficient evidence for mortality benefit. However, they recognize the safety profile and potential for individual benefit, particularly in patients with documented deficiency or refractory shock. Thiamine supplementation is recommended in high-risk populations, and corticosteroids are endorsed in vasopressor-refractory septic shock. Ongoing trials and emerging data may inform future updates to these recommendations.
Metabolic resuscitation in critical illness offers a promising adjunct to conventional hemodynamic support, targeting fundamental cellular processes implicated in organ dysfunction. While early observational studies showed remarkable outcomes, recent large-scale trials have tempered initial enthusiasm, highlighting the complexity of critical illness and the need for patient-specific approaches. Current evidence supports the safety of metabolic resuscitation and suggests potential benefits in select populations, but routine use awaits further validation. Clinicians should remain informed of evolving research and incorporate metabolic assessment and targeted supplementation as part of comprehensive critical care management.
1.
I Was Told I Had 6 Months to Live. That Was 20 Years Ago.
2.
Which Salvage Therapy Is Best for Recurrent Prostate Cancer?
3.
Aspirin Fails to Boost Survival in Colorectal Cancer Trial
4.
Chemoimmunotherapy Boosts Head and Neck Cancer Response
5.
Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.
1.
Essential Developments in Oncology for Healthcare Excellence
2.
Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained
3.
Understanding Apoplexy: Symptoms, Causes, and Treatment Options
4.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
5.
Understanding the Rare Disease: Werner Syndrome Explained
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Should We Use DARA Up Front As First-Line Therapy in MM?
2.
Navigating the Complexities of Ph Negative ALL - Part XIII
3.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
4.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation